Aardvark Therapeutics, Inc.
AARD
$8.69
-$0.66-7.06%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.73M | 4.46M | 3.70M | 2.94M | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.57M | 12.20M | 9.81M | 7.42M | -- |
| Operating Income | -15.57M | -12.20M | -9.81M | -7.42M | -- |
| Income Before Tax | -13.85M | -11.78M | -9.49M | -7.21M | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.85 | -11.78 | -9.49 | -7.21 | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.85M | -11.78M | -9.49M | -7.21M | -- |
| EBIT | -15.57M | -12.20M | -9.81M | -7.42M | -- |
| EBITDA | -5.09M | -- | -- | -- | -- |
| EPS Basic | -3.49 | -2.97 | -2.39 | -1.82 | -- |
| Normalized Basic EPS | -2.16 | -1.77 | -1.36 | -0.95 | -- |
| EPS Diluted | -3.49 | -2.97 | -2.39 | -1.82 | -- |
| Normalized Diluted EPS | -2.16 | -1.77 | -1.36 | -0.95 | -- |
| Average Basic Shares Outstanding | 15.89M | 15.86M | 15.85M | 15.84M | -- |
| Average Diluted Shares Outstanding | 15.89M | 15.86M | 15.85M | 15.84M | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
